Education > XRAY > Metastatic Breast Cancer

FORCE's eXaming the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you. XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program

1 through 10 of 76

Relevance: High

pointerRelevance

Strength of Science: High

pointerStrength of Science

Research Timeline: Post Approval

pointerResearch Timeline
View Related Clinical Trials

Study : Trodelvy clinical trial results likely practice-changing for people with metastatic triple-negative breast cancer

Most relevant for: People with metastatic triple-negative breast cancer

The ASCENT study confirmed an earlier study and showed that the smart drug sacituzumab govitecan-hizy (Trodelvy) improves outcomes for people with previously treated metastatic triple-negative breast cancer. These results further support the use of Trodelvy as a standard therapy for patients with pretreated metastatic triple-negative breast cancer. (11/20/20)

Read More
Trodelvy clinical trial results likely practice-changing for people with metastatic triple-negative breast cancer

Relevance: Medium-Low

pointerRelevance

Strength of Science: Medium-High

pointerStrength of Science

Research Timeline: Animal Studies

pointerResearch Timeline

Study : The buzz about honeybee venom: Promising early research to treat breast cancer

Most relevant for: People with breast cancer particularly those with HER2-positive or triple-negative breast cancer.

Early research showed that melittin, an ingredient in honeybee venom, may be used to treat HER2-positive and triple-negative breast cancers. This study found that melittin can kill cancer cells. The chemotherapy drug docetaxel more effectively killed breast cancer cells in mice when combined with melittin. It is not known whether melittin would be safe or affect cancer growth in people. While promising, more research must be done before melittin could be used to treat people.  (11/10/20)

Read More
The buzz about honeybee venom: Promising early research to treat breast cancer

Relevance: High

pointerRelevance

Quality of Writing: High

pointerQuality of Writing
View Related Clinical Trials

Personal Story : Coping with chemotherapy-induced hair loss

Most relevant for: People who receive chemotherapy for cancer treatment

Ovarian cancer survivor Stephanie Hess shared her personal story about how she coped with hair loss. This XRAY review also includes treatments to reduce this common side effect of chemotherapy. (9/28/20)

Read More
Coping with chemotherapy-induced hair loss

Relevance: Medium-High

pointerRelevance

Research Timeline: Post Approval

pointerResearch Timeline
View Related Clinical Trials

Guideline : FDA issues alert on a drug combination to treat triple-negative breast cancer

Most relevant for: People with metastatic triple-negative breast cancer

The immunotherapy drug Tecentriq (atezolizumab) is approved for use with Abraxane (nab-paclitaxel) to treat metastatic triple-negative breast cancer. Tecentriq is NOT approved for use with Taxol (paclitaxel). The Food and Drug Administration has issued an alert to doctors, researchers and patients warning that Tecentriq should not be used in combination with Taxol to treat patients with advanced triple-negative breast cancer. (09/18/20)

Read More
FDA issues alert on a drug combination to treat triple-negative breast cancer

Relevance: High

pointerRelevance

Strength of Science: High

pointerStrength of Science

Quality of Writing: High

pointerQuality of Writing
View Related Clinical Trials

Study : Among women with breast cancer, who should have genetic testing for an inherited mutation?

Most relevant for: Women diagnosed with breast cancer who do not know if they have an inherited mutation in a gene linked to breast cancer

Which breast cancer patients should consider genetic testing? Knowing whether you have an inherited mutation may inform the decisions you and your healthcare provider make about treatment. But it can also increase stress and anxiety. This XRAY reviews a study of how different guidelines affect genetic testing recommendations for people with breast cancer. (8/27/20)

Read More
Among women with breast cancer, who should have genetic testing for an inherited mutation?

Relevance: Medium-High

pointerRelevance

Strength of Science: Medium-High

pointerStrength of Science

Research Timeline: Human Research

pointerResearch Timeline
View Related Clinical Trials

Study : Promising research using a PARP inhibitor to treat metastatic breast cancer in people with an inherited PALB2 mutation or a tumor mutation in BRCA1 or BRCA2

Most relevant for: People with metastatic breast cancer with an inherited mutation or tumor with a BRCA mutation

Early results of a small study showed that women with metastatic breast cancer and an inherited  mutation in PALB2 or an acquired tumor mutation in BRCA1 or BRCA2 benefitted from the PARP inhibitor olaparib (Lynparza). (6/18/20)

Read More
Promising research using a PARP inhibitor to treat metastatic breast cancer in people with an inherited PALB2 mutation or a tumor mutation in BRCA1 or BRCA2

Relevance: High

pointerRelevance

Research Timeline: Post Approval

pointerResearch Timeline
View Related Clinical Trials

Update : FDA approves tucatinib (Tukysa) for metastatic Her2-positive breast cancer

Most relevant for: Patients with Her2-positive metastatic breast cancer

The FDA has approved the use of tucatinib (Tukysa) in combination with chemotherapy as a treatment for people with metastatic Her2-positive breast cancer. This  approval includes treatment of people whose breast cancer has spread to the brain. (4/29/20)

Read More
FDA approves tucatinib (Tukysa) for metastatic Her2-positive breast cancer

Relevance: High

pointerRelevance

Research Timeline: Post Approval

pointerResearch Timeline
View Related Clinical Trials

Update : FDA approves new treatment for metastatic triple-negative breast cancer

Most relevant for: People with metastatic triple-negative breast cancer who have received at least two prior lines of treatment

The FDA approved the use of sacituzumab govitecan-hizy (Trodelvy), a treatment drug for people with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease. (4/27/20)

Read More
FDA approves new treatment for metastatic triple-negative breast cancer

Topic : COVID-19 and Cancer

Most relevant for: People in treatment for cancer, or people scheduled for surgery

The current COVID-19 pandemic has led to many changes in our communities. In this XRAY review we focus on the intersection between COVID-19 and cancer: who may be immunosuppressed, coping with changes in surveillance or treatment, and evaluating and dealing with media. (4/13/20)

Este artículo está disponible en español.

Read More
COVID-19 and Cancer

Relevance: High

pointerRelevance

Quality of Writing: High

pointerQuality of Writing
View Related Clinical Trials

Personal Story : Improving the quality of life for people with metastatic breast cancer

Most relevant for: People diagnosed with metastatic breast cancer

Washington Post article described the cancer experience of a young woman living with metastatic breast cancer. It also highlights how integrative medicine and palliative care, including acupuncture, massage, yoga, pain management, mental health therapy and nutrition can improve quality of life for people with metastatic cancer. (3/10/20)

 

Read More
Improving the quality of life for people with metastatic breast cancer

This Portal Sponsored By:

Centers for Disease Control